608 results on '"Tillmann, Hans L"'
Search Results
2. Size Matters! Anti-HBs Titer and HBV Reactivation During Anti-TNF Therapy
3. Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury
4. Value of liver biopsy in the diagnosis of drug-induced liver injury
5. Review article: Recommendations for detection, assessment and management of suspected drug‐induced liver injury during clinical trials in oncology patients.
6. Trends in mortality from gastrointestinal, hepatic, and pancreatic cancers in the United States: A comprehensive analysis (1999–2020)
7. Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests
8. Role of Hepatitis B Surface Antibodies in Risk for Hepatitis B Virus Reactivation During Anti–Tumor Necrosis Factor Therapy
9. A Downside to Hepatitis C Virus Cure? Vigilance Is Needed Regarding Hepatitis B Virus Reactivation, Organ Rejection, or Hepatocellular Carcinoma Progression
10. Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury
11. Hepatotoxicity; Drug-Induced Liver Injury
12. Signatures in drug-induced liver injury
13. DILI Associated with Skin Reactions
14. Tools for causality assessment in drug-induced liver disease
15. Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination
16. It's not all about the virus—On the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B
17. A novel quantitative computer-assisted drug-induced liver injury causality assessment tool (DILI-CAT)
18. Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease
19. Viren und die Entstehung hämatologischer Neoplasien
20. Hepatitis C Virus Infection: When Is a Cure Not a Cure?
21. Associations of gender and a proxy of female menopausal status with histological features of drug‐induced liver injury
22. Death and liver transplantation within 2 years of onset of drug‐induced liver injury
23. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients
24. Endgames
25. Persistence of Occult Hepatitis B after Removal of the Hepatitis B Virus-Infected Liver
26. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C
27. The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation
28. Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report
29. Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury
30. Hepatitis C Virus Infection: Its Role in Pathogenesis
31. Su1338: ROLE OF HEPATITIS B SURFACE ANTIBODY FOR THE RISK OF HBV REACTIVATION DURING ANTI-TNF THERAPY
32. A novel phenotype‐based drug‐induced liver injury causality assessment tool (DILI‐CAT) allows for signal confirmation in early drug development
33. Sequencing and Genotyping of Hepatitis C Virus in Patients with Autoimmune Hepatitis Type 2
34. A Rationalized Approach to the Treatment of Patients Infected with Hepatitis B
35. Use of Thrombopoietic Agents for the Thrombocytopenia of Liver Disease
36. A Polymorphism Near IL28B Is Associated With Spontaneous Clearance of Acute Hepatitis C Virus and Jaundice
37. Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction
38. An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response
39. Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus
40. Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin
41. “On demand” sedation for colonoscopy with or without auricular acupuncture is non-inferior and may improve quality metrics compared to “upfront” sedation.
42. MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection
43. Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy
44. GB Virus C/Hepatitis G Virus Infection: A Favorable Prognostic Factor in Human Immunodeficiency Virus-Infected Patients
45. The Association of Genetic Variants with Hepatic Steatosis in Patients with Genotype 1 Chronic Hepatitis C Infection
46. Acute HCV: Will IL28B Testing Change the Paradigm?
47. Prognostic Implications of Lactate, Bilirubin, and Etiology in German Patients With Acute Liver Failure
48. Hepatitis C virus infection and the brain
49. Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C
50. Screening for and treating hepatitis B virus in patients with HIV infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.